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The Office of Technology Development (OTD) of the National Cancer Institute (NCI) is responsible for negotiating
Cooperative Research and Development Agreements (CRADAs), whereby the knowledge resulting from NCI
investigators' government-sponsored research is developed in collaboration with universities and/or industry into
new products of importance for the diagnosis and treatment of cancer and acquired immunodeficiency syndrome
(AIDS). The NCI has recently executed a unique "clinical trials" CRADA and is developing a model agreement
based upon it for the development and commercialization of products for the diagnosis and treatment of cancer and
AIDS. NCI drug screening, preclinical testing, clinical trials, and AIDS program capabilities form the basis for this
new technology development/technology transfer vehicle. NCI's extensive drug screening program and "designer
foods" program serve as potential sources of investigational new drugs (INDs) and cancer preventatives.
Collaborations between NCI and pharmaceutical companies having the facilities, experience, and expertise necessary
to develop INDs into approved drugs available to the public are being encouraged where the companies have
proprietary rights to INDs, or where NCI has proprietary rights to INDs and invites companies to respond to a
collaborator announcement published in the Federal Register. The joint efforts of the NCI and the chosen
collaborator are designed to generate the data necessary to obtain pharmaceutic regulatory approval from the Food
and Drug Administration (FDA) to market the drugs developed, and thereby make them available to health care
providers for the diagnosis and treatment of cancer and AIDS.
INTRODUCTION
The Office of Technology Development is organizationally located in the Office of the Director of the National
Cancer Institute. The National Cancer Institute is one of the thirteen Institutes of the National Institutes of Health.
The National Institutes of Health is a part of the Public Health Service, which in turn is part of the Department of
Health and Human Services.
The mission of the National Institutes of Health is to conduct biomedical and behavioral research into the treatment
and control of disease, to positively benefit the health of the American people. As a main source of funding for
medical research in the United States, the National Institutes of Health is a national resource for the evaluation of
new disease therapies. Historically, the National Cancer Institute has been the most important effector in the
discovery and development of new anticancer agents. More recently, the National Cancer Institute has also played
a leading role in the discovery and development of anti-AIDS agents such as azidothymidine (AZT) and
dideoxyinosine (ddI).
Cancer and AIDS research efforts at the National Cancer Institute are both basic and applied. Basic biomedical and
molecular biology research being conducted include sequencing studies and studies of the molecular actions of drugs
and mutagens. Applied diagnostic and treatment research being conducted includes: methods and materials to detect
early cancer; methods and materials to detect human immunodeficiency virus (HIV) infection; and clinical trials to
determine the efficacy of anti-cancer and anti-AIDS agents.
The Office of Technology Development serves as the National Cancer lnstitute's focal point for the implementation
of the laws, policies, rules and regulations related to the implementation of the Federal Technology Transfer Act
of 1986. The Office is responsible for the administration of activities related to collaborative agreements,
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confidentiality agreements, material transfer agreements, inventions, patents, licensing and royalties. Office of
Technology Development staff members provide advice, guidance and assistance to National Cancer Institute
scientists and staff, and review and analyze planned agreements to ensure that they comport with applicable National
Cancer Institute, National Institutes of Health, Public Health Service, and Department of Health and Human Services
policy and procedures.
The Office of Technology Development interacts with several other National Institutes of Health technology transfer
components. Among these are: the Patent Policy Board; the National Institutes of Health Office of Technology
Transfer; the various Institute Technology Development Coordinators; and extramural components, including the
Office of Extramural Programs. The Patent Policy Board oversees the technology transfer program for the Public
Health Service, and makes policy recommendations to Public Health Service agency heads. The Office of
Technology Transfer serves the following centralized functions for the National Institutes of Health: preparation,
filing and prosecution of domestic and foreign patent applications,utilizing the services of its own Patent Branch,
outside contract attorneys, and the National Technical Information Service; marketing and licensing of technology
and inventions, either directly or through the Center for the Utilization of Federal Technology, Department of
Commerce; and drafting of model agreements. Each of the Institutes of the National Institutes of Health has a
Technology Development Coordinator who participates in the interactive stages of patent prosecution and licensing
activities. Two Institutes also have established offices for the transfer of technology. The National Cancer Institute
has established the Office of Technology Development; and the National Institute of Allergy and Infectious Diseases
has established the Technology Transfer Branch. The extramural component includes grants, contracts, cooperative
research and development agreements, informal clinical trial agreements, memoranda of understanding, and
confidentiality agreements; for drug screening and discovery, and clinical trials with private industry. Through the
office of Extramural Programs, grantee institutions report patentable inventions developed using Federal funds, and
communicate the grantees' decisions regarding the assignment of rights to those inventions.
The Office of Technology Development was established as the result of a series of legislative enactments that were
designed to transfer Federal technology to industry, to state and local governments, and to universities. Among these
legislative enactments are: Federal patent law; the Bayh-Do!e Patent and Trademark Act of 1980; the Stevenson-
Wydler Technology Innovation Act of 1980; the Federal Technology Transfer Act of 1986; and Executive Order
125991 of 1987. Federal patent law (35 U. S. C. at §§ 200-212) authorizes the licensing of Government-owned
patent rights. Under it, "... Each Federal agency is authorized to ... grant non-exclusive, exclusive, or partially
exclusive licenses under federally owned patent applications, patents, or other forms of protection obtained, royalty-
free or for royalties or other consideration, and on such terms and conditions, including the grant of a license of
the rights of enforcement pursuant to the provisions of chapter 29 of this title as determined appropriate in the public
interest; .... " The Bayh-Dole Act of 1980 allows nonprofit organizations and small business to retain rights to
inventions (patents) or other intellectual property (trademarks, copyrights) developed under Federal grant or contract
funding. This Act has been amended to allow Federal laboratories operated by nonprofit organizations to similarly
retain intellectual property rights and commercialize Federally sponsored inventions. The Stevenson-Wydler
Technology Innovation Act of 1980 establishes the policy that it is the duty of each Federal laboratory to transfer
Federal technology to industry, to state and local governments, and to universities. However, it was not until the
passage of the Technology Transfer of 1986, that Federal laboratories had effective incentives to encourage both
the Federal scientists and collaborators in the state, local and private sectors to participate and accomplish this goal.
The Federal Technology Transfer Act (15 U.S.C. § 3710, "Utilization of Federal Technology') of 1986 amended
the Stevenson-Wydler Technology Innovation Act of 1980 to authorized Federal laboratories to enter into
Cooperative Research and Development Agreements (CRADAs), and to grant intellectual property rights in advance
to collaborators for inventions made in whole or in part by Federal employees under the CRADA. The Federal
Technology Transfer Act requires that agencies establish cash award programs for inventors and non-inventors for
their contributions to technology transfer, and that laboratory directors recognize the competitive advantage Congress
intended technology transfer to grant United States business. A 1989 amendment to the Federal Technology Transfer
Act authorizes government-owned, contractor-operated (GOCO) facilities to enter into CRADAs so that technology
developed for the government by private parties can also be transferred. Executive Order 12591 of April 10, 1987,
"Facilitating Access to Science and Technology', orders Federal laboratories to transfer new knowledge from the
research laboratories to universities and to the private sector (to "privatize" Federal research inventions), assisting
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them in the development of new products and processes, thereby broadening our national technology base, and
strengthening United States manufacturers' competitive position in the international economic arena.
Legislation is pending that would further enable technology transfer from the Federal sector. Currently, Federal
employees are prohibited from copyrighting any work developed as part of their official duties. Under consideration
is the protection by copyright of computer software and other material developed by Federal employees under a
CRADA.
MODEL COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT
AND RELATED POLICY
The National Institutes of Health/Alcohol, Drug Abuse and Mental Health Administration (NIH/ADAMHA) Model
Cooperative Research and Development Agreement is a contractual mechanism for technology transfer, under which
information and materials are exchanged between collaborators. The Articles and Appendices of the
NIH/ADAMHA Model Agreement are as follows, with National Cancer Institute additions indicated:
Article 1. Introduction
Article 2. Definitions
Article 3. Cooperative Research
Article 4. Reports
Article 5. Financial and Staffing Obligations
Article 6. Title to Property
Article 7. Intellectual Property Rights and Applications
Article 8. Licensing
Article 9. Proprietary Rights and Publication*










NIH/ADAMHA Policy Statement on CRADAs and Intellectual Property Licensing
Research Plan
Financial and Staffing Contributions of the Parties
Exceptions or Modifications to this CRADA
NCI adds "Intellectual Contributions of the Parties" to this Article
NCI adds "Potential Patentability of Subject Inventions" to this Article
Several NIH/ADAMHA policy considerations impact upon the terms agreed to by the Government under a CRADA.
National Cancer Institute investigators are free to choose their research topics, provided their choices are consistent
with the mission of the Institute and the program of their particular laboratories. This research freedom cannot be
constrained by the conditions of a CRADA or a related licensing agreement. Nor can the scientists' participation
in a cooperative research plan restrict his ability to disseminate research results freely in both publications and public
fora. Provision is made for reasonable delays in this dissemination only for the purpose of filing patent
application(s), which filing is, in fact, encouraged.
Under a CRADA there is an exchange between the collaborators of intellectual and/or technical resources that are
not otherwise reasonably available. Provision is made for personnel, services, facilities and equipment to be
exchanged between the collaborator and the National Cancer Institute. Funds may flow from the collaborator to the
National Cancer Institute; however, in no case may funds flow from the National Cancer Institute to the
collaborator.
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The CRADA collaborator is chosen on the basis of scientific expertise and commercialization capabilities. When
the Government has the intellectual lead, a Federal Register notification may be appropriate. NIH/ADAMHA will
give special consideration to entering into CRADAs with small business firms and consortia involving small business
firms. Further, preference will be given to businesses located in the United States, or which agree to manufacture
substantially in the United States products which embody inventions developed under CRADAs.
Proprietary information may be exchanged and maintained as confidential under a CRADA, since Freedom of
Information does not require the release of "trade secrets and commercial or financial information ... [that] are
privileged and confidential'. Secrecy is routinely maintained under National Cancer Institute drug screening
programs and during the Food and Drug Administration regulatory approval process. Proprietary information under
CRADAs is maintained as confidential as long as is necessary to accomplish the research plan. However, in no case
will secrecy be maintained once an invention has been patented.
The time-limited right to exclude others from making, using, or selling an invention, which is conveyed by a license
is used as an incentive for collaborators to invest in product development under a CRADA. Time-limited options
to negotiate non-exclusive, partially exclusive, or exclusive licenses may be granted in advance to CRADA
collaborators. When granting licenses to inventions developed wholly by NIHIADAMHA investigators or jointly
with a collaborator under a CRADA, the Government retains a n0nexciusive, irrevocable, paid-up_license to practice
the invention or to have the invention practiced throughout the world by or on behalf Of the U.S, Government. The
Government also requires the grant of a research license for inventions made wholly by a collaborator under a
CRADA. Further, NIH/ADAMHA reserve the right under any license granted to the collaborator, to grant research
licenses to third parties.
Requests for exclusive commercialization licenses must include a development and commercialization plan. After
an exclusive license is granted, reports on progress toward utilization of the invention are required. NIH/ADAMHA
reserv_ ihe right to grant several, separate exclusive iicen_in various fields of_. Exclusive licenses wi|! have
"best effort" clauses, and may be terminated when a licensee is not _tiveiy engaged in an effort to produce product,
or a licensee cannot meet _rket demand. Exclusive licensees mustfiot unreasonably deny requests for sub|icense
in unused fields of use, or requests for cross license rights from future CRADA collaborators when derivative rights
are necessary for a CRADA to go forward, and the exclusive licensee has been given a reasonable opportunity to
be a party to the CRADA.
A pricing clause will be found in every CRADA since policy states that "DHHS has a concern that there be a
reasonable relationship between the pricing of a licensed product, the public investment in that product, and the
health and safety needs of the public. Accordingly, exclusive commercialization licenses granted for NIH/ADAMHA
intellectual property rights may require that this relationship be supported by reasonable evidence."
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTS
FOR THE CLINICAL DEVELOPMENT OF ANTI-CANCER AND/OR ANTI-AIDS AGENTS
When a compound is discovered or developed by the National Cancer Institute that shows promise as an anti-cancer
or an anti-AIDS agent, the involvement of a private firm is sought, since the Nafiofial Cancer institute does not take
drugs to market. TIle early-involvement of a pha_ceutica| firm permits substantial _st sharing between the
Government and the private sector, and can speed the commercial availability of effective agents. Industry is asked
to invest its resources to bring an agent from the discovery stage through subsequent development, clinical trials,
regulatory approvals, and ultirrmtely into commercial production. An exclusive license may be granted to the
industrial collaborator in cases where substantial additional risk, time and cost must be undertaken prior to
successful commercialization. An option to negotiate such a license may be granted in advance under a CRADA
for the clinical development of an agent.
Under a CRADA for the clinical development of an agent, national, multicenter clinical trials in various research
settings, and trials in combination with other agents, can be planned and coordinated. Efforts to investigate and
evaluate alternative sources of the agent can also be planned and coordinated.
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In addition to standard CRADA provisions, a CRADA for the clinical development of an anti-cancer or anti-AIDS
agent may also contain terms regarding:
The formation and functioning of a Clinical Research Team, or Steering Committee
Provision for supply of drug up to New Drug Application (NDA) filing, including amounts for
compassionate use
Provision for Investigational New Drug Application (IND) sponsorship, and for cross-referencing of INDs
Summary of completed and ongoing preclinical and clinical testing and data
Provision for data collection
Provision for New Drug Application (NDA) filing
Provision of support staff for Group C distribution
Conveyance of orphan drug status
License of pre-dating compounds or methods of use apart from CRADA
Publication clause: "Nothing shall prevent the timely publication of the results of clinical trials or pre-
clinical research."
A recently executed example of a CRADA for Clinical Development is one for the clinical development of taxol.
Taxol is a promising new drug for the treatment of refractory ovarian cancer. Taxol was discovered during the NCI-
sponsored screening of extracts of over 35,000 plant species. It is a natural product that is in short supply. In return
for the significant financial investment of procuring sufficient taxol for clinical trials, and for exploring alternative
natural and synthetic sources, and for prosecuting the NDA, the collaborator has been given exclusive access to the
clinical data, and conveyance of the orphan drug status that was granted taxol by the FDA. This is an unusual
CRADA, since taxol is not patented, and other companies are, therefore, free to work on taxol, as well as its
analogues.
Ncrs UNIQUE RESEARCH CAPABILITIES
NCI has research capabilities uniquely suited to cooperative research for the clinical development of anticancer and
anti-AIDS agents. NCI has the largest staff and funding among the Institutes of the National Institutes of Health,
and possesses unique capabilities in support of clinical development efforts. NCI's drug screening and development
programs include acquisition and synthesis of novel compounds, in vitro screening, in vivo assays, preclinical
testing, clinical trials, and AIDS program capabilities.
NCI's Clinical Therapy Evaluation Program (CTEP), within the Division of Cancer Treatment, is researching the
uses of therapeutic compounds supplied by intramural as well as extramural researchers and pharmaceutical
companies. CTEP designs and implements the development plans for new agents; it files INDs with FDA,
permitting DCT to act as a drug sponsor; and it is responsible for the contracts and cooperative agreements under
which most clinical testing takes place. Through grants, contracts and cooperative agreements, NCI funds a large,
multicenter clinical trials network, including cooperative groups, new drug development contractors, and other
investigators at cancer centers and university hospitals. More than 500 investigators and approximately 500
institutions are involved; and over 100 compounds are currently in various stages of clinical testing.
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NCI overshoes the only Government Owned Contractor Operated (GOCO) facility at NIH, at the Frederick Cancer
Research and Development Center (NCI-FCRDC). Five separate NCI-FCRDC contract operations provide: basic
rese.arch, operations and technical support, computer service, s, library services, and animal production. The
following NCI Divisions have intramural, extramural and clinical activities at NCI-FCRDC: the Division of Cancer
Etiology (DCE); the Division of Cancer Treatment (DCT, including the Developmental Therapeutics Program and
Biological Respon_ Modifiers Program); the Division of Cancer Biology, Diagnosis and Centers (DCBDC), and
the Division of Cancer Prevention and Control (DCPC). GOCO contractors at NCI-FCRDC are engaged in basic
research into the causes and biology of cancer, and furnish the following technical support services: support for new
DCT programs for in vitro screening of antitumor and anti-AIDS cornpounds, including the development of large-
scale natural products extraction capability; support for the Biological Response Modifiers Program's experimental
clinical trials at a nearby outpatient facility _d an inpatient capability located ata/ocal hospital; support for AIDS
vaccine development program efforts at NCI-FCRDC and an outside subcontract network; repositories for cell lines,
natural product compounds, and other research materials; managing the NCI Supercomputer Center, with special
emphasis on mathematical biology in biomedical research.
NCI's Cancer Network includes: Cancer Information Service (CIS), a national toll-free telephone service that
provides immediate answers to cancer-related questions from cancer patients, families, the public, and health
professionals; Cancer Centers, a program of cancer research centers across the country which significantly
contributes to progress in basic research, clinical studies, and cancer prevention and control; Community Clinical
Oncology Program (CCOP), a program affording community physicians and their patients the opportunity to
participate in NCI-approved cancer treatment and cancer prevention and control clinical trials; Physicians Data
Query (PDQ), an on-line computer system that provides state-of-the-art information on cancer detect|on, diagnosis
and treatment; Cooperative Group Outreach Program (CGOP), designed to increase patient enrollment in clinical
trials and to upgrade the skills of c0mmunity physicians and other healthpr0fessionals; Surveillance, Epidemiology,
and End Results (SEER) Program, population-based cancer registries that permit monitoring of cancer incidence,
mortality and survival, and is a key tool for assessing progress against cancer.
RESEARCH INITIATIVES WITHIN THE DIVISIONS OF TIIE NATIONAL CANCER INSTITUTE
Research initiatives within the Divisions of the National Cancer Institute of interest to potential CRADA
collaborators are as follows. Re_arch initiatives within the Division of Cancer Etiology (DCE) include dietary
mutagen studies, and an investigation of the relationship between human papilloma viruses and cancer risk. Within
the Division of Cancer Biology, Diagnosis and Centers (DCBDC), new discoveries are providing new strategies
for potentially inhibiting cancer invasion metastasis formation and growth. Using a panel of about 60 human tumor
cell lines, the Division of Cancer Treatment (DCT) is routinely screening about 20,000 synthetic compounds and
natural products extracts annually for anti-cancer activity. Screening of potential anti-AIDS drugs also has been
carried out in HIV-infected cells at a rate of about 20,000 synthetic compounds and natural products extracts
annually. DCT's research activities al_ include: clinical strategies to overcome multi-drug resistance; human gene
therapy; clinical development of taxol; adoptive immunotherapy; and tumor suppressor genes.
NCI PRECLINICAL AND CLINICAL TREATMENT RESEARCH EFFORTS
Pharmaceutical industry interactions with NCI for the testing and joint development of agents are possible at all
stages of antitumor screening, preclinical toxicology, and clinical testing.
NCI's preclinical research efforts include new drug discovery through natural product screening and rational drug
design; and the preclinical discovery and development of biological response modifiers, including such research
areas as monoclonal antibodies, ceil-mediated cytotoxic therapy, targeting of growth factor oncogenes and tumor-
tumor suppressor genes, and hematopoietic growth factors
NCI's clinical research efforts include: enhancement of the effectiveness of chemotherapy; immunotherapy; gene
therapy; differentiation therapy; radiation oncology; diagnostic imaging; and clinical trials, including investigational
drug and chemoprevention trials.
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RECENT/CURRENT NATIONAL CANCER INSTITUTE CRADAS
AIDS Vaccine Development: H1V gpl60
Generation and Characterization of Monoclonal Antibodies to Carcinoma Associated Antigens
Retroviral-Mediated Transfer for AIDS Therapy
Retroviral-Mediated Gene Transfer into Bone Marrow Cells and T and B Lymphocytes
Research in the Field of Early Detection of Lung Cancer
Evaluation of cDNA Clones Related to Cancer Metastases
Transforming Growth Factor-cdpseudomonas Exotoxin Hybrid Proteins
Cytokines for Enhancing Drug Delivery and Pharmacologic Action
Clinical Development of Taxol
Interleuldn-2/pseudomonas Exotoxin
Development of Methods for PCR Amplification of DNA Sequences Directly from Clinical Specimens
Human Cytochrome p-450 cDNA Expression and Mutagenesis
Clinical Development of PALA
Testing of Antigens for Improvement of IL-2 Therapy
Immunoglobulin and Immunotoxin Therapeutics for HIV Infections and AIDS
The Function of Two Novel, Inducible Proteins Secreted by Activated T Cells
Novel CD4 Targeted Anti-HIV Agents
Construction of a Multiwell Cell Settling Chamber
AIDS Vaccine
Single Chain Bispecific Antibody
Hair Follicle Cell Biology, Biochemistry and Molecular Biology
Human Papillomavirus (HPV) Infection and Cervical Dysplasia
Development of Nontoxic Aqueous Chemiluminescent Systems for Use in Pbotodynamic Therapy
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RECENT/CURRENT NCI CRADA COLLABORATORS
Abbott Laboratories/Johns Hopkins University
American Cyanamid Company
Amgen Incorporated
Bristol-Myers Squibb
Cetus Corporation
Creative BioMolecules
Dow Chemical
Genetic Therapy, Inc.
Gentest Corporation
Hoffmann-LaRoche
Imrnuno-U. S.
Integrated Genetics
Lofstrand Labs .
Merck
Molecular Oncology
Molecular Vaccines
Neuro Probe, Inc.
Sandoz Forschungsinstitut
U.S. Bioscience
Upjohn Company
Virogenetics
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